Brind.
  1. Tariffs and uncertainty, coupled with slow stimulus activity in China, are delaying biopharma investments.
  2. Harvard Bioscience is facing revenue decline due to macro uncertainty over tariffs and ongoing issues regarding NIH funding.

John Duke is the President and CEO of Harvard Bioscience, which is currently managing sales weighted toward lower-margin products in China.

1 report, 1 independent Updated Aug 11
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

John Duke is the President and CEO of Harvard Bioscience, which is currently managing sales weighted toward lower-margin products in China.

Who's involved

What this event is mainly about
Harvard BioscienceChina

Keep exploring

Part of

Harvard Bioscience is facing revenue decline due to macro uncertainty over tariffs and ongoing issues regarding NIH funding. All 1 developments

Within Tariffs and uncertainty, coupled with slow stimulus activity in China, are delaying biopharma investments.

The entities involved

Coverage

Newest first; wire copies grouped